Guanhao Biotech Co Ltd
Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products primarily in China. It offers NormalGEN, a dura repair patch; GrandNeuro, a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological … Read more
Guanhao Biotech Co Ltd (300238) - Net Assets
Latest net assets as of September 2025: CN¥493.49 Million CNY
Based on the latest financial reports, Guanhao Biotech Co Ltd (300238) has net assets worth CN¥493.49 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥774.51 Million) and total liabilities (CN¥281.01 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥493.49 Million |
| % of Total Assets | 63.72% |
| Annual Growth Rate | 20.14% |
| 5-Year Change | -34.75% |
| 10-Year Change | -24.66% |
| Growth Volatility | 63.75 |
Guanhao Biotech Co Ltd - Net Assets Trend (2007–2024)
This chart illustrates how Guanhao Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Guanhao Biotech Co Ltd (2007–2024)
The table below shows the annual net assets of Guanhao Biotech Co Ltd from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥467.59 Million | +2.48% |
| 2023-12-31 | CN¥456.26 Million | +5.89% |
| 2022-12-31 | CN¥430.88 Million | -42.41% |
| 2021-12-31 | CN¥748.16 Million | +4.40% |
| 2020-12-31 | CN¥716.66 Million | +1.78% |
| 2019-12-31 | CN¥704.14 Million | -39.06% |
| 2018-12-31 | CN¥1.16 Billion | -4.73% |
| 2017-12-31 | CN¥1.21 Billion | -16.77% |
| 2016-12-31 | CN¥1.46 Billion | +134.83% |
| 2015-12-31 | CN¥620.62 Million | +16.74% |
| 2014-12-31 | CN¥531.61 Million | +6.72% |
| 2013-12-31 | CN¥498.16 Million | +9.70% |
| 2012-12-31 | CN¥454.11 Million | +4.92% |
| 2011-12-31 | CN¥432.79 Million | +198.49% |
| 2010-12-31 | CN¥144.99 Million | +88.42% |
| 2009-12-31 | CN¥76.95 Million | +107.91% |
| 2008-12-31 | CN¥37.01 Million | +79.07% |
| 2007-12-31 | CN¥20.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Guanhao Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 31278405162.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥265.16 Million | 48.89% |
| Other Comprehensive Income | CN¥36.77 Million | 6.78% |
| Other Components | CN¥562.03 Million | 103.63% |
| Total Equity | CN¥542.36 Million | 100.00% |
Guanhao Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Guanhao Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Time Technoplast Limited
NSE:TIMETECHNO
|
$440.42 Million |
|
Beijing Bayi Space LCD Technology Co Ltd
SHG:688181
|
$440.48 Million |
|
Global Medical REIT Inc.
NYSE:GMRE
|
$440.68 Million |
|
Baotou Huazi Industry Co Ltd
SHG:600191
|
$440.68 Million |
|
CorMedix Inc
NASDAQ:CRMD
|
$440.19 Million |
|
Guangzhou Guangri Stock Co Ltd
SHG:600894
|
$440.17 Million |
|
i3 Verticals Inc
NASDAQ:IIIV
|
$440.17 Million |
|
Flaircomm Microelectronics Inc Ordinary Shares - Class A
SHE:301600
|
$440.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guanhao Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 520,593,839 to 542,358,105, a change of 21,764,266 (4.2%).
- Net income of 27,416,909 contributed positively to equity growth.
- Dividend payments of 2,464,230 reduced retained earnings.
- Other comprehensive income increased equity by 36,767,023.
- Other factors decreased equity by 39,955,436.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥27.42 Million | +5.06% |
| Dividends Paid | CN¥2.46 Million | -0.45% |
| Other Comprehensive Income | CN¥36.77 Million | +6.78% |
| Other Changes | CN¥-39.96 Million | -7.37% |
| Total Change | CN¥- | 4.18% |
Book Value vs Market Value Analysis
This analysis compares Guanhao Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.17x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 96.53x to 8.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.17 | CN¥16.17 | x |
| 2008-12-31 | CN¥0.30 | CN¥16.17 | x |
| 2009-12-31 | CN¥0.52 | CN¥16.17 | x |
| 2010-12-31 | CN¥0.83 | CN¥16.17 | x |
| 2011-12-31 | CN¥1.77 | CN¥16.17 | x |
| 2012-12-31 | CN¥1.84 | CN¥16.17 | x |
| 2013-12-31 | CN¥2.03 | CN¥16.17 | x |
| 2014-12-31 | CN¥2.12 | CN¥16.17 | x |
| 2015-12-31 | CN¥2.38 | CN¥16.17 | x |
| 2016-12-31 | CN¥5.63 | CN¥16.17 | x |
| 2017-12-31 | CN¥4.35 | CN¥16.17 | x |
| 2018-12-31 | CN¥4.29 | CN¥16.17 | x |
| 2019-12-31 | CN¥2.68 | CN¥16.17 | x |
| 2020-12-31 | CN¥2.75 | CN¥16.17 | x |
| 2021-12-31 | CN¥2.96 | CN¥16.17 | x |
| 2022-12-31 | CN¥1.83 | CN¥16.17 | x |
| 2023-12-31 | CN¥2.01 | CN¥16.17 | x |
| 2024-12-31 | CN¥1.98 | CN¥16.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guanhao Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.06%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.26%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.39x
- Recent ROE (5.06%) is above the historical average (1.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 13.60% | 12.56% | 0.55x | 1.97x | CN¥743.38K |
| 2008 | 19.17% | 20.16% | 0.57x | 1.67x | CN¥3.39 Million |
| 2009 | 18.73% | 21.99% | 0.54x | 1.59x | CN¥6.72 Million |
| 2010 | 22.31% | 31.52% | 0.43x | 1.63x | CN¥17.84 Million |
| 2011 | 9.34% | 31.45% | 0.26x | 1.15x | CN¥-2.86 Million |
| 2012 | 8.15% | 25.19% | 0.27x | 1.19x | CN¥-8.38 Million |
| 2013 | 8.14% | 24.08% | 0.29x | 1.15x | CN¥-9.24 Million |
| 2014 | 9.42% | 26.32% | 0.31x | 1.17x | CN¥-3.06 Million |
| 2015 | 10.91% | 28.02% | 0.28x | 1.39x | CN¥5.26 Million |
| 2016 | 4.08% | 18.21% | 0.19x | 1.21x | CN¥-82.48 Million |
| 2017 | 4.93% | 12.76% | 0.26x | 1.47x | CN¥-59.04 Million |
| 2018 | 3.96% | 9.98% | 0.28x | 1.42x | CN¥-69.67 Million |
| 2019 | -65.41% | -106.27% | 0.38x | 1.62x | CN¥-536.47 Million |
| 2020 | 6.38% | 10.66% | 0.39x | 1.55x | CN¥-26.43 Million |
| 2021 | 9.40% | 15.07% | 0.45x | 1.40x | CN¥-4.71 Million |
| 2022 | -63.43% | -81.59% | 0.56x | 1.38x | CN¥-356.37 Million |
| 2023 | 5.96% | 7.67% | 0.60x | 1.30x | CN¥-21.05 Million |
| 2024 | 5.06% | 7.26% | 0.50x | 1.39x | CN¥-26.82 Million |
Industry Comparison
This section compares Guanhao Biotech Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guanhao Biotech Co Ltd (300238) | CN¥493.49 Million | 13.60% | 0.57x | $440.30 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |